Editor in Chief: Mary Cushman @RPTHJournal Reprint Collection: Spotlighting our top content from the past year www.rpthjournal.org
Editor-in-Chief Mary Cushman, MD, MSc University of Vermont, Burlington, VT, USA mary.cushman@uvm.edu Deputy Editor Cihan Ay Medical University of Vienna, Austria Associate Editors Pantep Angchaisuksiri Ramathibodi Hospital, Mahidol University, Thailand Suzanne Cannegieter Leiden University Medical Center, The Netherlands Lana Castellucci University of Ott awa, Canada Johnny Mahlanguh University of the Witwatersrand and Nati onal Health Laboratory Service, South Africa Vania M. Morelli The Arcti c University of Norway, Norway Suely Meireles Rezende Federal University of Minas Gerais, Brazil Social Media Associate Editors Yazan Abou-Ismail University of Utah, USA Megan Brown Emory University, USA Bethany Samuelson Bannow Oregon Health & Science University, USA Kristen Sanfi lippo Washington University of St Louis, USA Yoti s Senis INSERM, France Michelle Sholzberg St. Michael’s Hospital, Canada Henri M. H. Spronk Maastricht University, The Netherlands Neil Zakai University of Vermont, USA Illustrated Materials Associate Editor Michelle Sholzberg St. Michael’s Hospital, Canada Managing Editor Hunter Hayes RPTH@jjeditorial.com Editorial Board Maria Aleman USA Roopen Arya UK Geoff rey Barnes USA Marc Blondon Switzerland Ilaria Canobbio Italy Marc Carrier Canada Caterina Casari France Aurelien Delluc France Carsten Depperman Germany Sabine Eichinger Austria Anna Falanga Italy Emmanuel Favaloro Australia Inger Lise Gade Denmark Nigel Key USA Paul Kim Canada Erik Klok Netherlands Oliver Königsbrügge Austria Johanna Kremer-Hovinga Switzerland Lisa Baumann Kreuziger USA Joyce Ching Mei Lam Singapore Mandy Lauw Netherlands Michelle Lavin Ireland Ang Li USA Pamela Lutsey USA Mike Makris UK Maria Elisa Mancuso Italy Eileen Merriman New Zealand Saskia Middeldorp The Netherlands Fionnuala Ní Áinle Ireland Fernanda Orsi Brazil Maha Othman Canada Marlien Pieters South Africa Anat Rabinovich Israel Julie Rayes UK Julia Riedl Austria Wolfram Ruf USA Isabelle Salles-Crawley UK Per Morten Sandset Norway Jordan Schaefer USA Midori Shima Japan Bob Siegerink Netherlands Nicholas Smith USA Kristi Smock USA Deirdra Terrell USA Johannes Thaler Austria Grace Thomas France Timo Voegtle Germany Tzu-Fei Wang Canada Jeff rey Zwicker USA Methodological Reviewers Nicholas S. Roetker Hennepin Healthcare Research Insti tute USA Bob Siegerink Leiden University Netherlands
Aims and Scope Research and Practice in Thrombosis and Haemostasis (RPTH) is an official journal of the International Society on Thrombosis and Haemostasis (ISTH). Complementing its flagship journal, theJournal of Thrombosis and Haemostasis (JTH), RPTHprovides a dedicated Open Access home for science and discourse among researchers, clinicians, nurses, allied health professionals, and patients. RPTHis a “living journal” and serves as a jumping point for digital discussion. It also reflects the current era of inter-disciplinary scientific discovery and new methods of knowledge dissemination and the wide reach of ISTH by featuring articles from all corners of the globe. RPTHprovides rigorous, rapid peer review and immediate dissemination of research reports from basic, clinical, translational and population or public health science. The Journal is interested in quality, outcomes, dissemination and implementation science, seeking studies and trials on novel care delivery, including in areas of resource constraint around the world. Digital discussion is encouraged through our Twitter account @RPTHJournal and with hashtags #RPTH, #RPTHEditorial, #RPTHCommentary, #RPTHReview, #RPTHTutorial, #CoagCapsule, #RPTHIllustratedReview Open Access and Copyright All articles published by Research and Practice in Thrombosis and Haemostasis are fully open access: immediately freely available to read, download, and share. All Research and Practice in Thrombosis and Haemostasis articles are published under the terms of the Creative Commons Attribution-NonCommercial-No Derivs license (‘‘CC-BY-NC-ND’’), which permits users to copy, distribute, and transmit an article as long as the author is attributed, the article is not used for commercial purposes, and the work is not modified or adapted in any way. An exception is made for Contributors funded by agencies requiring use of a Creative Commons Attribution license (‘‘CC-BY’’)which permits others to use, distribute, reproduce, remix, tweak, and build upon the work in any medium (even commercially) as long as the Contribution is credited for the original creation. Such funders include the Research Councils UK, the Wellcome Trust and other funders recognized by the Publisher as requiring a CC-BY license, who may publish their Contributions under a CC-BY license. Copyright on any research article published by Research and Practice in Thrombosis and Haemostasis is retained by the author(s). Authors grant Elsevier a license to publish the article and identify itself as the original publisher. Further information about open access license and copyright can be found at: https://www.elsevier.com/open-access Contact Details Research and Practice in Thrombosis and Haemostasis is published by Elsevier Inc, 230 Park Avenue, Suite 800, New York, NY 10169, USA. Editorial Correspondence/Information for Authors: rpth@jjeditorial.com Production Editor: Kelly Hawker jtha@elsevier.com Advertising: Kate Lach k.lach.1@elsevier.com Purchasing Print Reprints Print reprints of Open Access articles can be purchased from https://www.medreprints.com/ Disclaimer The Publisher, International Society on Thrombosis and Haemostasis, and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, International Society on Thrombosis and Haemostasis and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, International Society on Thrombosis and Haemostasis and Editors of the products advertised. Elsevier Open Access articles posted to repositories or websites are without warranty from Elsevier of any kind, either express or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. To the fullest extent permitted by law Elsevier disclaims all liability for any loss or damage arising out of, or in connection, with the use of or inability to use the content. For submission instructions and all the latest information, visit http://rpth.isth.org For online submission, visit https://mc.manuscriptcentral.com/rpth Research and Practi ce in Thrombosis and Haemostasis is published by Elsevier Inc, 230 Park Avenue, Suite 800, New York, NY 10169, USA. Editorial Correspondence/Informati on for Authors: rpth@jjeditorial.com Producti on Editor: Kelly Hawker rpth@elsevier.com Adverti sing: Kate Lach k.lach.1@elsevier.com #RPTHEditorial, #RPTHCommentary, #RPTHReview, #RPTHTutorial, #CoagCapsule, #RPTHIllustratedReview
Reprint Collecti on: Spotlighti ng our top content from the past year CONTENTS Editorial RPTH Year 6 Reprint Collecti on Mary Cushman MD, MSc Reprinted from Res Pract Thromb Haemost, 7 (6) (2023), 100146. RPTH Editor’s Award RPTH announces annual Editor’s Award recipients for 2023 Reprinted from Res Pract Thromb Haemost, 7 (2) (2023), 100095. Editorials of Interest Are women equal? Considering impact of therapeuti c aborti on bans on science Mary Cushman MD, MSc Reprinted from Res Pract Thromb Haemost, 6 (4) (2022), e12742. Equity in scienti fi c publishing: 2022 results from Research and Practi ce in Thrombosis and Haemostasis Elizabeth C. Pendlebury BA, Mary Cushman MD, MSc Reprinted from Res Pract Thromb Haemost, 7 (1) (2023), 100059. Hot Topics Being Cited and Read Online Therapeuti c anti coagulati on to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial Marc Blondon MD, Sara Cereghetti MD, Jérôme Pugin MD, Christophe Marti MD, Pauline Darbellay Farhoumand MD, Jean-Luc Reny PhD, Alexandra Calmy MD, Christophe Combescure PhD, Lucia Mazzolai MD, Olivier Pantet MD, Zied Ltaief MD, Marie Méan MD, Sara Manzocchi Besson MD, Séverin Jeanneret MD, Hans Stricker MD, Helia Robert-Ebadi MD, Pierre Fontana PhD, Marc Righini MD, Alessandro Casini MD Reprinted from Res Pract Thromb Haemost, 6 (4) (2022), e12712.
Participate and contribute in the SSC subcommittees Join discussions and share your knowledge with peers and leading experts Join scientific communities to enrich your experience and education Collaborate in the development of standards and guidelines Explore the new interactive online platform for ISTH members NEW FEATURES: Questions? membership@isth.org Expand your network and participate in discussions about the latest scientific discoveries and clinical practices of conditions related to thrombosis and hemostasis. TO GET STARTED VISIT my.isth.org Login using your ISTH credentials Share and review documents through an interactive workspace Expand your network with the Member Directory: Connect with colleagues Collaborate in the Open Forum and strengthen your network connections
Prophylacti c emicizumab for hemophilia A in the Asia-Pacifi c region: A randomized study (HAVEN 5) Renchi Yang MD, Shujie Wang MD, Xuefeng Wang MD, Jing Sun MD, Ampaiwan Chuansumrit MD, Jianfeng Zhou MD, Christophe Schmitt PharmD, Wanling Hsu PhD, Jeff rey Xu MD, Lindong Li MD, Tiff any Chang MD, Xielan Zhao MD Reprinted from Res Pract Thromb Haemost, 6 (2) (2022), e12670. The Hemophilia Joint Health Score version 2.1 Validati on in Adult Pati ents Study: A multi center internati onal study Jean St-Louis MD, FRCPC, Audrey Abad BSc, Sharon Funk DPT, Merlyn Tilak MPT, Stephen Classey PT, Nichan Zourikian BSc, PT, Paul McLaughlin PT, MSc, MCSP, Sébasti en Lobet PT, PhD, Grace Hernandez PT, Stacie Akins PT, Anna J. Wells PT, MSc, MCSP, SRP, Marilyn Manco-Johnson MD, Judy John MD, Steve Austi n MBBS BMedSci FRACP FRCPA, Prati ma Chowdary MD, Cedric Hermans MD, Diane Nugent MD, Nihal Bakeer MD, Sarah Mangles MD, MBBS, MD (Res), FRCP, FRCPath, Pamela Hilliard BSc, PT, Brian M. Feldman MD, MSc, FRCPC Reprinted from Res Pract Thromb Haemost, 6 (2) (2022), e12690. Evaluati on of the Khorana score for predicti on of venous thromboembolism in pati ents with multi ple myeloma Kristen M. Sanfi lippo MD, MPHS, Kenneth R. Carson MD, PhD, Tzu-Fei Wang MD, MPH, Suhong Luo MS, Natasha Edwin MD, Nicole Kuderer MD, Jesse M. Keller MPD, MPHS, Brian F. Gage MD, MSc Reprinted from Res Pract Thromb Haemost, 6 (1) (2022), e12634. Illustrated Review Arti cles Thromboti c microangiopathies: An illustrated review Mouhamed Yazan Abou-Ismail MD, Sargam Kapoor MD, Divyaswathi Citla Sridhar MD, Lalitha Nayak MD, Sanjay Ahuja MD, MSc Reprinted from Res Pract Thromb Haemost, 6 (3) (2022), e12708. Fishing for answers to hemostati c and thromboti c disease: Genome editi ng in zebrafi sh Azhwar Raghunath PhD, Allison C. Ferguson BS, Jordan A. Shavit MD, PhD Reprinted from Res Pract Thromb Haemost, 6 (5) (2022), e12759. Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review Annie Zhu MD, Phavalan Rajendram MD, Eric Tseng MD, MScCH, Shelagh B. Coutt s MD, MSc, Amy Y.X. Yu MD, MSc Reprinted from Res Pract Thromb Haemost, 6 (6) (2022), e12795. Fibrinolysis: an illustrated review Rebecca A. Risman BSc, Nicholas C. Kirby BSc, Britt any E. Bannish PhD, Nathan E. Hudson PhD, Valerie Tutwiler PhD Reprinted from Res Pract Thromb Haemost, 7 (2) (2023), 100081.
ISTH State of the Art 2022 Top Pick Impact of novel hemophilia therapies around the world Margareth C. Ozelo MD, PhD, Gabriela G. Yamaguti -Hayakawa MD Reprinted from Res Pract Thromb Haemost, 6 (3) (2022), e12695. Hot Topics on Twitt er A call to acti on: MTHFR polymorphisms should not be a part of inherited thrombophilia testi ng Thomas G. Deloughery MD, MACP, FAWM, Beverley J. Hunt OBE, Geoff rey D. Barnes MD, MSc, Jean M. Connors MD, The WTD Steering Committ ee, Cihan Ay, Stefano Barco, Lana Castellucci, Gabriela Cesarman-Maus, Erich Vinicius De Paula, Mert Dumantepe, Maria Cecilia Guillermo Esposito, Federica Fedele, Lai Heng Lee, Claire McLintock, Eriko Morishita, Charles Marc Samama, Helen Okoye, Todd Robertson Reprinted from Res Pract Thromb Haemost, 6 (4) (2022), e12739. Do physicians contribute to psychological distress aft er venous thrombosis? Kersti n de Wit MBChB, MD, MSc Reprinted from Res Pract Thromb Haemost, 6 (1) (2022), e12651. Clinical relapse of immune-mediated thromboti c thrombocytopenic purpura following COVID-19 vaccinati on William Deucher, Senthil Sukumar, Spero R. Cataland MD Reprinted from Res Pract Thromb Haemost, 6 (1) (2022), e12658.
Received: 30 March 2023 - Accepted: 30 March 2023 https://doi.org/10.1016/j.rpth.2023.100146 EDITORIAL RPTH year 6 article collection Research and Practice in Thrombosis and Haemostasis (RPTH) is an open access online-only journal of the International Society on Thrombosis and Haemostasis (ISTH). We are celebrating our sixth birthday in 2023! That RPTH is not printed is wonderful for us, allowing us to be nimble in publishing research quickly after acceptance so that it is available to all completely freely. It also allows us to publish without page limits imposed by a paper journal. Each year for the annual ISTH Congress, we print an issue for attendees to enjoy. In our first year, this was our inaugural issue and excitement filled the Convention Centre Dublin as thousands of attendees grabbed their copies and enjoyed our very first publication. When the pandemic started in 2020, we did not produce a printed issue as the Milan Congress was quickly transitioned to a virtual Congress, and this continued in 2021 for the Philadelphia Congress. We returned to an in-person Congress in London in July 2022 and released our firstprint edition in 3 years—this issue was a commemorative collection of previously published articles celebrating our fifth anniversary, the “Year 5 Innovation Celebration Issue” [1,2]. It was really fun to put together and included“Top5’s” from different categories, ranging from original articles to illustrated review articles to our top social media performing articles. We are continuing with the newly started tradition from July 2022 by presenting in this collection some of the best articles published in 2022-2023. We are celebrating our RPTH Editor’s Award recipients, Tessa Noordermeer, MSc; Jie Sun, MD; and Matthias M. Engelen, MD. We share editorials related to our work in equity, diversity and inclusion, Hot Topics, Illustrated Review articles, an ISTH 2022 State of the Art article, and articles that have gained traction on our social media feed. We hope you will enjoy this year’s collection, and head to our website, www.rpthjournal.org, to view the great science coming out and the article collections that we curate for you. Follow our Twitter feed @RPTHJournal as well, where you can find tweets on most articles as they are published. This is the final print collection of my tenure as editor in chief, and it has been a joy to bring these to you! Mary Cushman MD, MSc Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA Correspondence Mary Cushman, Department of Medicine, Larner College of Medicine at the University of Vermont, 360 South Park Dr, Colchester, VT 05446, USA. Email: mary.cushman@uvm.edu TWITTER Mary Cushman @MaryCushmanMD REFERENCES [1] 5-Year Anniversary Edition: Research and Practice in Thrombosis and Haemostasis. https://www.rpthjournal.org/content/collection-5-yearanniversary-edition; 2022 [accessed March 30, 2023]. [2] Cushman M. RPTH 5-year anniversary celebration collection. Res Pract Thromb Haemost. 2023;7:100105. ©2023 The Author. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Res Pract Thromb Haemost. 2023:e100146 www.rpthjournal.org - 1 of 1 https://doi.org/10.1016/j.rpth.2023.100146 Reprinted from Res Pract Thromb Haemost. 2023;7:100146 htt ps://doi.org/10.1016/j.rpth.2023.100146
Received: 16 February 2023 - Accepted: 18 February 2023 https://doi.org/10.1016/j.rpth.2023.100095 RPTH announces annual Editor’s Award recipients for 2023 Research and Practice in Thrombosis and Haemostasis (RPTH) has named three early career investigators as the recipients of the 2023 RPTH Editor’s Awards. The RPTH Editor’s Awards are presented annually to three early career investigators who submit exemplary articles as selected by a jury of editors. Recipients of this award receive a travel grant and complimentary registration to the ISTH 2023 Congress, providing the opportunity to network with other exceptional researchers in thrombosis and hemostasis. In order to qualify for this award, candidates must be the first author and member of the ISTH in one of the early career membership categories at the time the article is submitted. Candidates may indicate their interest to be considered for the award during the submission process at rpth.isth.org. 2023 RPTH Editor’ s Awards Recipients: Tessa Noordermeer, M.Sc., Interference in point-of-care International Normalized Ratio monitoring in patients with lupus anticoagulant is correlated with anti-β2-Glycoprotein I antibody titers Jie Sun, M.D., Low-dose immune tolerance induction in severe hemophilia A children with high-titer inhibitors: Type of factor 8 mutation and outcomes Matthias M. Engelen, M.D., Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: the DAWn-Antico study Res Pract Thromb Haemost. 2023;7:e100095 www.rpthjournal.org - 1 of 1 https://doi.org/10.1016/j.rpth.2023.100095 Reprinted from Res Pract Thromb Haemost. 2023;7:100095 htt ps://doi.org/10.1016/j.rpth.2023.100095
Res Pract Thromb Haemost. 2022;6:e12742. Պ|Պ1 of 3 https://doi.org/10.1002/rth2.12742 wileyonlinelibrary.com/journal/rth2 !;1;b;7Ĺ Ɛƒ - ƑƏƑƑՊ|Պ 11;r|;7Ĺ Ɛƒ - ƑƏƑƑ DOI: 10.1002/rth2.12742 EDITORIAL Are women equal? Considering impact of therapeutic abortion bans on science I usually write editorials providing advice to authors and reviewers about scientific publishing. These include pieces about expanding the reach of your research, use of illustration, and promotion of inclusiveness in publishing by minoritized groups such as women, people of color, and those in resource-limited countries. Recent events in the United States prompted me to consider and discuss here the connections of reproductive health justice with diversity in science and medicine. I believe that striking down Roe v Wade in the United States will negatively impact the future workforce and productivity of the science and medicine community in the United States, reversing the progress of the past 5 decades. Many readers may be aware that the US Supreme Court looks like it will reverse precedent set 49 years ago (when I was a 9-year-old girl) in the Roe v Wade decision, which ruled in a 7-2 bipartisan decision that the Constitution of the United States protects a person's liberty to choose to have a therapeutic abortion without excessive government restriction. Striking down Roe will allow states to ban, and even criminalize, therapeutic medical or surgical abortion services. If this eventuates, 13 of our 50 states that now have “trigger laws” will ban all therapeutic abortion services and some would even include a ban for women who were victims of rape or incest1; in some states, health care providers, or possibly patients seeking |_bv _;-Ѵ|_ 1-u;ķ 1oѴ7 ]o |o f-bѴĺ vblbѴ-u ml0;u o= v|-|;v -u; Ѵbh;Ѵ to enact bans shortly after (covering more than half of states altogether). Women with financial ability may still access these services 0 |u-;Ѵbm] |o - v|-|; _;u; v;ub1;v u;l-bm Ѵ;]-Ѵĺ lom] ol;m who have therapeutic abortion, 62% are younger than age 30 years (12% are teens) and 49% live in poverty2; these women will have far less access. Thus, the ruling will profoundly worsen socioeconomic based disparities in women's health that are already prominent in the United States. The persistent racial disparity in maternal mortality affecting non-Hispanic Black women will widen; these women make up of 28% of women having therapeutic abortion and who have a 3.5-fold greater risk of dying during or after pregnancy than non- Hispanic White women.3 mѴ ƒƕѷ o= l;ub1-mv -]u;; |_-| -0ou|bom v_oѴ7 0; bѴѴ;]-Ѵ bm all or most cases, whereas 61% agree that it should be legal in all or most cases.4 !;v;-u1_ -m7 u-1|b1; bm $_uol0ovbv -m7 -;lov|-vbvՔ ŐRPTH) has been working since we launched in 2017 to assure equal opportunity for women in scientific publishing. By this, we aim to have a future where unconscious biases are checked, and where women, men, the transgendered and gender-fluid persons are treated equally. If rights to reproductive freedom in the United States are taken away by a minority opinion, this will reverberate through society such that women will be less able to enter the scientific or medical profession, participate effectively in our competitive research workforce, and enact agency and control over the course of their own health and lives. The situation that rings as most damaging is that a victim of rape or incest would be required to become a mother after such a horrific crime. It is difficult for most to imagine the lifelong implications for these women and for all women desiring this treatment who are denied. Our effort at RPTH to equalize the playing field for scientific publishing is working; at last count, after a gradual rise over the years, we met our goal for the proportion of women authors to equal the proportion of women members of our society, the International Society on Thrombosis and Haemostasis.5 To achieve this, we assembled a woman-inclusive editorial team, with the current proportion of women being 42% of the editors and 69% of the editorial board. This creates a culture of inclusion and can contribute to less biased peer review. We consider author gender when inviting review articles and commentaries, discuss unconscious bias regularly at team meetings, and encourage a general goal to have at least one woman peer reviewer for every article. To provide a snapshot of representation and to challenge the thrombosis and hemostasis community to be more inclusive, in fall 2020 we tabulated the proportion of women on editorial teams for journals in our field.6 Table 1 shows those results and current tabulations. Results are flawed because they do not use self-reported gender and assume name or appearance are proxies for gender, which is not uniformly true. I applaud that 40% of journals increased their representation; all of these except RPTH had lower than equitable representation in 2020. The other journals stayed constant or declined, with only a few having equitable representation. Remarkably, three journals consistently had <~ƑƏѷ ol;m om |_;bu |;-lvĺ v bm This is an open access article under the terms of the u;-|b; ollomv ||ub0|bomŊ om oll;u1b-ѴŊ o ;ubv License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. š ƑƏƑƑ $_; |_ouvĺ Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). Reprinted from Res Pract Thromb Haemost. 2022;6:e12742 htt ps://doi.org/10.1002/rth2.12742
Ƒ o= ƒՊ|Պ ՊՍ EDITORIAL 2020, I call on journals to adopt policies for editorial teams to match the gender diversity of the readership. My actions to assure equity as a journal editor reflect my goal to normalize the presence of women in our science and medicine community. Women's rights to control their own bodies have increased their participation in the workforce over the past 49 years. I have grave concerns about the negative impact of losing the right to reproductive health services in the United States on the ability of women, especially those who are minoritized or poor, to participate in, and enhance, our science and medicine community. We need these women in our ranks to advance health care quality and equity, and to make strides in science discovery. Whatever a person's individual decisions might be on therapeutic abortion for themselves, I respect and honor that. That said, I believe women are equal to men in all ways and should have equal ability under the law to control their own reproductive health. We are going backwards to a time when I was 9 years old and Roe v Wade was decided by an overwhelming majority. What will happen to our girls and women? What oppressions will come next? What will happen in other countries? Undoubtedly, young women will not have the opportunities I had. I ask you to consider these issues. KEYWORDS abortion, authorship, reproductive health services, women ACKNOWLEDGMENT I thank Elizabeth Pendlebury for research compiling editor team gender data. Mary Cushman MD, MSc Larner College of Medicine, University of Vermont, Burlington, Vermont, USA Correspondence Mary Cushman, Larner College of Medicine, University of (;ulom|ķ ƒѵƏ "o|_ -uh uĺķ oѴ1_;v|;uķ ($ ƏƔƓƓѵķ &" ĺ Email: mary.cushman@uvm.edu ORCID Mary Cushman https://orcid.org/0000-0002-7871-6143 TWITTER Mary Cushman @MaryCushmanMD REFERENCES Ɛĺ bl;m; ĺ )_-| bv - |ub]];u Ѵ-ĵ m7 _b1_ v|-|;v _-; |_;lĵ ; York Times; 2022. https://www.nytimes.com/2022/05/04/us/ abortion-trigger-laws.htmlĺ 11;vv;7 - ƐƑķ ƑƏƑƑĺ TABLE 1Պ!;ru;v;m|-|bom o= ol;m om foum-Ѵ ;7b|oub-Ѵ |;-lv =ou |_uol0ovbv -m7 _;lov|-vbvŊ u;Ѵ-|;7 foum-Ѵvķ ƑƏƑƏŋ ƑƏƑƑ Journal title Fall 2020 Spring 2022 % Women on editorial team Woman editor in chief? % Women on editorial team Woman editor in chief? Increased representation Research and Practice in Thrombosis and Haemostasis 51 Yes 55 Yes Journal of Thrombosis and Haemostasis 19 o 50 o Blood 37 Yes 45 Yes Arteriosclerosis, Thrombosis, and Vascular Biology 25 o 39 o Journal of the American Heart Association 33 o 37 o Thrombosis Research 26 1 each 34 1 each Similar representation The Lancet Haematology 64 Yes 62 Yes American Journal of Hematology 53 o 54 o Haemophiliaa 32 o 34 o British Journal of Haematology 23 o 23 o Thrombosis and Haemostasis 18 o 19 o Journal of Thrombosis and Thrombolysis 14 o 16 o Decreased representation Platelets 35 o 26 o Circulation 27 o 24 o European Journal of Haematology 21 o 14 o Note: Teams include editor, deputy or associate editors, and editorial board members. Within each group of longitudinal change, journals are ordered as highest to lowest current representation of women. Those shown in red have consistently poor representation of women. a3/60 in 2022 with unknown gender.
ՊՍՊ|Պƒ o= ƒ EDITORIAL 2. Guttmacher Institute. United States abortion demographics. https://www.guttmacher.org/united-states/abortion/demographicsĺ 11;vv;7 - ƐƑķ ƑƏƑƑĺ ƒĺ -1 oul-m ķ $_ol- ķ ;1Ѵ1;ut ķ o;ѴѴ ĺ !-1b-Ѵ -m7 ethnic disparities in maternal mortality in the United States using enhanced vital records, 20162017. Am J Public Health. 2021;111:1673-1681. doi:ƐƏĺƑƐƏƔņ ĺƑƏƑƐĺƒƏѵƒƕƔ Ɠĺ ; !;v;-u1_ ;m|;uĺ l;ub1-Ľv -0ou|bom t-m7-uĺ ƑƏƑƑĺ https:// www.pewresearch.org/religion/2022/05/06/americas-abortion- quandary/ĺ 11;vv;7 - Ɛƒķ ƑƏƑƑĺ Ɣĺ ;m7Ѵ;0u ķ v_l-m ĺ mm-Ѵ u;rou| om ;tb|ķ 7b;uvb|ķ and inclusion: research and practice in thrombosis and haemostasis is meeting its goals. Res Pract Thromb Haemost. 2021;5:e12610. doi:10.1002/rth2.12610 6. Pendlebury EC, Cushman M. Diversity, equity, and inclusion in publishing: calling thrombosis and hemostasis journals to action in support of women. Res Pract Thromb Haemost. 2020;4:1076-1079. doi:10.1002/rth2.12434 How to cite this article: v_l-m ĺ u; ol;m ;t-Ѵĵ Considering impact of therapeutic abortion bans on science. Res Pract Thromb Haemost. 2022;6:e12742. doi:10.1002/ rth2.12742
Received: 19 January 2023 - Accepted: 19 January 2023 https://doi.org/10.1016/j.rpth.2023.100059 EDITORIAL Equity in scientific publishing: 2022 results from Research and Practice in Thrombosis and Haemostasis In accordance with our Statement on Diversity, Equity and Inclusion (Figure 1), Research and Practice in Thrombosis and Haemostasis (RPTH) tabulates and publishes the characteristics of its authors, reviewers, and editorial board each year. The purpose is to detect possible unconscious bias in peer review and editorial practices. Our goals this year are to evaluate the following: 1. That gender representation of authors and reviewers reflects the membership of the International Society on Thrombosis and Haemostasis (ISTH). 2. Baseline data on race or ethnicity of authors and reviewers. 3. For increased publications from under-represented countries. In general, since 2017 when RPTH launched, we have seen a steady increase in the representation of female authors [1–4]. Over time, we have collected self-reported data for gender and added race or ethnicity. Here, we report data on gender, self-reported race or ethnicity, and location of authors, reviewers, and editorial board members from July 2021 to June 2022. Our benchmark for gender distribution is the ISTH membership, which is now 49% for women, a figure that has risen from 44% in 2018. 1 | AUTHOR GENDER Figure 2 shows the percentage of female authors over time. In 20212022, there were 1396 authors of accepted articles. Self-identified gender (male, female, nonbinary, and prefer not to say) was available for 48%, and gender was inferred using genderize.io for the remainder (requiring 70% probability of gender being known based on name to assign gender). Of 1396 authors, 47.6% were women, 50.9% men, and 21 were in the other groups (1.5%). Women made up 49.3% of senior authors and 56.8% of first authors. For 35 invited articles, 51.4% of those invited (ie, the senior author) were women, 45.7% men, and 2.9% preferred not to disclose. Including the coauthors of these articles, 52.9% were women, 45.9% men, and 1.2% preferred not to disclose. Taken together, we are meeting our goal of similar gender distribution to the ISTH membership, and exceeding this for invited authors. One caveat in the data is that in some countries or institutions, it is common for the first author to be the corresponding author even when they are a trainee, which we would then count as the senior author erroneously. In previous years, we were able to manually identify the senior author (typically the author in the last position on the author list) based on the editor’s knowledge, but with increasing numbers of manuscripts, we no longer do this. The overall impact on the results is likely small. In a new analysis performed this year, Figure 3 shows the proportion of women by decision status. Compared with accepted articles, the proportion of female corresponding authors was similar for articles that were rejected after peer review (46% of corresponding authors of 338 articles), and this proportion was lower for articles rejected without peer review (ie, desk-rejected articles; 41.8% of corresponding authors of 165 articles). We can conclude based on these data that there is no evidence of gender bias affecting women in the decision to reject. 2 | AUTHOR RACE AND ETHNICITY Because there is no global classification for race and ethnicity, we used an open-ended question for self-reporting, “Based on your region of the world, how would you classify your race/ethnicity?” Authors are asked this question when they log in to the manuscript submission system, so data remain incomplete. At the time of last year’s report, we had information for 197 authors, and this year, we have 826. With more responses, there were more descriptors this year. Table 1 shows that far fewer authors elected not to identify ZWd, ^ƚĂƚĞŵĞŶƚ ŽŶ ŝǀĞƌƐŝƚLJ͕ ƋƵŝƚLJ͕ ĂŶĚ /ŶĐůƵƐŝŽŶ ZWd, ďĞůŝĞǀĞƐ ƚŚĂƚ ĚŝǀĞƌƐŝƚLJ ŝŶ Ăůů ĨŽƌŵƐ ǁŝůů ĂĚǀĂŶĐĞ ƐĐŝĞŶƟĮĐ ĚŝƐĐŽƵƌƐĞ͘ tĞ ĐŽŵŵŝƚ ƚŽ ďƵŝůĚŝŶŐ Ă ƉƵďůŝƐŚŝŶŐ ĐƵůƚƵƌĞ ŽĨ ĚŝǀĞƌƐŝƚLJ͕ ĞƋƵŝƚLJ͕ ĂŶĚ ŝŶĐůƵƐŝŽŶ ƚŚĂƚ ǁŝůů ŝŶĐƌĞĂƐĞ ƚŚĞ ƉĂƌƟĐŝƉĂƟŽŶ ŽĨ ǁŽŵĞŶ͕ ƚŚŽƐĞ ĨƌŽŵ ƵŶĚĞƌƌĞƉƌĞƐĞŶƚĞĚ ƌĂĐĞͬ ĞƚŚŶŝĐ ŐƌŽƵƉƐ͕ ĞĂƌůLJ ĐĂƌĞĞƌ ƉƌŽĨĞƐƐŝŽŶĂůƐ͕ ĂŶĚ ƚŚŽƐĞ ĨƌŽŵ Ăůů ƌĞŐŝŽŶƐ ŽĨ ƚŚĞ ǁŽƌůĚ ĂƐ ĂƐƐŽĐŝĂƚĞ ĞĚŝƚŽƌƐ͕ ĞĚŝƚŽƌŝĂů ďŽĂƌĚ ŵĞŵďĞƌƐ͕ ĂƵƚŚŽƌƐ͕ ĂŶĚ ƉĞĞƌ ƌĞǀŝĞǁĞƌƐ͘ FIGURE 1 RPTH Statement on Diversity, Equity, and Inclusion. ©2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Res Pract Thromb Haemost. 2023;7:e100059 www.rpthjournal.org - 1 of 5 https://doi.org/10.1016/j.rpth.2023.100059 Reprinted from Res Pract Thromb Haemost. 2023;7:e100059 htt ps://doi.org/10.1016/j.rpth.2023.100059
with a group; 4.7% vs 13.2%. Over time, representation of both White and Black authors increased, with other groups remaining similar. Because we have incomplete race data and cannot assign race or ethnicity to authors with missing data, we will need to wait for more complete data to allow interpretation. At the least, we can say that authors are more willing over time to share this information, possibly because they increasingly recognize the reasons for reporting. 3 | AUTHOR COUNTRY/REGION OF THE WORLD The RPTH team strives to assure that authors from underrepresented countries receive equitable peer review. This is discussed regularly at team meetings. Equity requires careful attention to the selection of peer reviewers, de-emphasizing language usage issues in manuscripts, and a culture of fairness and understanding of the limitations to conducting research in under-resourced countries. Table 2 shows the region of the world of first authors for manuscripts published over time. In 2021-2022, manuscripts from North America have decreased proportionately, those from Europe and Oceania remained constant, and those from Asia, South America, the Middle East, and Africa increased. Based on thesefindings, it appears that the editorial team’s efforts are working. 4 | EDITORIAL BOARD A diverse editorial team should lead to diversity of peer reviewers and authors. The current Editor in Chief and associate editors identify as 8 women and 6 men, with 10 self-reporting as White, 1 Black, 1 Asian, 1 multiracial, and 1 not applicable. The editorial board is selected from among our peer reviewers, and membership is updated each year, Ϭ ϭϬ ϮϬ ϯϬ ϰϬ ϱϬ ϲϬ ůů ^ĞŶŝŽƌ ůů ^ĞŶŝŽƌ WĞƌĐĞŶƚĂŐĞ ŽĨ tŽŵĞŶ ƵƚŚŽƌƐ ϮϬϭϳͲϭϴ ϮϬϭϴͲϭϵ ϮϬϭϵͲϮϬ ϮϬϮϬͲϮϭ ϮϬϮϭͲϮϮ ůů ƵƚŚŽƌƐ /ŶǀŝƚĞĚ ƵƚŚŽƌƐ й FIGURE 2 Percentage of female authors over time. The horizontal bar indicates that in 2021, 49% of ISTH members identified as female (an increase over prior years). Ϭ ϭϬ ϮϬ ϯϬ ϰϬ ϱϬ ϲϬ ĐĐĞƉƚĞĚ ZĞũĞĐƚĞĚ ;ĂůůͿ ĞƐŬ ZĞũĞĐƚĞĚ WĞƌĐĞŶƚĂŐĞ ŽĨ tŽŵĞŶ ƵƚŚŽƌƐ ďLJ ĞĐŝƐŝŽŶ ^ƚĂƚƵƐ й FIGURE 3 Proportion of female authors by manuscript decision. The horizontal bar indicates that in 2021, 49% of ISTH members identified as female (an increase over prior years). 2 of 5 - EDITORIAL
aiming to involve committed reviewers and early-career members. The board is asked to participate in review and authorship. The current board includes 22 women and 20 men (none reporting other sexes); 57.1% identify as Caucasian, 14% European, 9.5% Asian, 7.1% more than one, 4.8% Hispanic/Latino, 4.8% other, 2.4% Australian, and 2.4% Arab. As for location, 45.2% reside in Europe, 38.1% in North America, 4.8% in Asia, 4.8% in South America, and 7.1% in Oceania. Figure 4 shows the location of authors, reviewers, and editorial team members in 2021-2022. Relative to the editorial team proportions, reviewers are more likely to be located in North America and less likely to be located in South America and Oceania; authors are less likely to be located in South America and Oceania and are more likely to be located in Asia and North America. These data suggest areas for improvement in engagement. As time passes, the presence of editorial team members from less-represented regions may increase the participation of authors and reviewers from those regions. 5 | REVIEWER ATTRIBUTES RPTH was fortunate to have 288 peer reviewers from July 2021 to June 2022. We are grateful to each one. Similar to authors, we aspire that reviewers have a similar gender distribution as ISTH members. Based on self-identification (available for all), 38.9% of reviewers were women, 59.4% were men, and 1.7% preferred not to say or were nonbinary. In the previous year, we reported only reviewers who reviewed 2 or more manuscripts, and 42.7% were women. Based on current data, we need to improve the proportion of female reviewers, and the associate editor team is discussing this. Systematic efforts to increase women’s peer review representation TABLE 1 Self-reported race ethnicity of authors. Race or ethnicity group Number (%) in each group Verbatim responses within each group, all years 2020-2021 (n = 197) 2021-2022 (n = 826) Caucasian or White 103 (52.2%) 474 (57.4%) Anglo, Australian, British, British White, Canadian Caucasian, White, White South African, White UK, White-Non-Hispanic Asian 35 (17.8%) 153 (18.5%) Asian, Asian (Japanese), Asian-Non-Hispanic, Chinese, Dravidian, East Asian, East Indian, Han Chinese, Hindustani, Indian, Japanese, Korean, Malay, Mongoloid, Non-Hispanic Indian, Sinhalese, South Asian, South Asian/ Indian, Southeast Asian, Thai European 16 (8.1%) 55 (6.7%) Armenian, Aryans, Belarusian, Caucasian Dutch, Caucasian European, Caucasian Italian, Caucasian Netherlands, Caucasian Swiss-Italian, Dutch, European, Finnish, French, German, Greek, Greek Caucasian, Irish, Irish Caucasian, Italian, Mediterranean Caucasian, Norwegian, Scandinavian, Turkish, Viennese, White European, White Hungarian, White Irish Hispanic 4 (2.0%) 25 (3.0%) Blanco (Spanish White), Hispanic, Hispanic Caucasian, Hispanic/Latinx, Latin/ Latino/Latinx, Spanish, White Hispanic, White Latin-American Middle Eastern 4 (2.0%) 28 (3.4%) Arab, Arabe, Caucuses/Middle Eastern, Chaldo-Asserian Iranian, MENA (Middle Eastern/North African), Middle Eastern, Middle Eastern/Syrian, Pakistani, Persian, Saudi, White-Israeli, White-Arab, WhiteMiddle Eastern, Moslim, Syrian Jewish 2 (1.0%) 9 (1.1%) Jewish, White-Jewish Black 1 (0.5%) 18 (2.2%) African American, African-Black, Afro-Carribean, Black, Black/African, Black/Afro-Carribean 2 or More 6 (3.0%) 25 (3.0%) Asian American, Asian Canadian, Asian/Indian, Asian/Latin-American, Biracial, Caucasian-Asian, Chinese-Canadian, Half Asian, Malaysian Chinese, Mixed, Multiracial, NZ European, White-Other No race ethnicity 26 (13.2%) 39 (4.7%) Do not want to say, human, N/A, other, not relevant TABLE 2 Representation of published manuscripts by region of the world in RPTH, 2017-2021. Region of the world Number of articles published July 2017December 2019 n = 520 January 2020August 2021 n = 250 July 2021June 2022 n = 192 North America 267 (51.3%) 132 (52.8%) 83 (43.2%) Europe 205 (39.4%) 97 (38.8%) 77 (40.1%) Asia 26 (5%) 14 (5.6%) 16 (8.3%) Oceania 14 (2.7%) 2 (0.8%) 5 (2.6%) South America 4 (0.8%) 2 (0.8%) 4 (2.1%) Middle East 3 (0.6%) 2 (0.8%) 4 (2.1%) Africa 1 (0.2%) 1 (0.4%) 3 (1.6%) EDITORIAL - 3 of 5
are effective without posing undue burdens on women [5]. In a previous RPTH analysis, women were more likely to accept our invitations to review [2]; hence, inviting more women to review should raise the percentage. We have race or ethnicity data on 269 reviewers who selfidentified as 60.2% White, 12.3% Asian, 11.5% European, 2.6% Hispanic, and a smaller number of other groups. As for region of the world, 46.8% were from North America, 41.6% from Europe, 4.8% from Asia, and a smaller number from other regions. These percentages are similar to the regions of authors. 6 | ISTH ACTIVITIES In alignment with its Diversity, Equity and Inclusion Statement [6], the ISTH collects self-reported data on gender and race or ethnicity of members. RPTH has collected self-reported race data with an openended question, and ISTH asks the members to choose one or more groups from a list: Aboriginal/Pacific Islander (origins of Australia or thePacific Islands), Asian (origins of Asia, East Asia, or Southeast Asia), Black (origins of Africa), Hispanic/Latin (origins of Central or South America or culture of Spanish origin), Indian/South Asian (origins of Indian subcontinent), Native American/Indigenous (origins of the Americas), White (origins of Europe), Prefer to self-identify (please specify), and Prefer not to answer. RPTH will adopt this question going forward, allowing direct comparison of our authors with ISTH membership distribution so that we can consider goals based on ISTH membership. 7 | WHAT IS HAPPENING IN THE LITERATURE? As before, we continue to call on other journals to share their results on equity and diversity. We note that reports continue to be published demonstrating inequity in publishing and appear to be increasing in the years since we have been reporting RPTH data [7–9]. In one shocking example, considering Scopus-indexed medical journals published in Latin America, women comprised only 12.9% of those in editorial leadership positions [10]. We have reported inequity for some journals in the thrombosis and hemostasis field [11] and await improvements. Inequity in authorship for women was prominent in sub-Saharan Africa [12]. Some journals have expressed a commitment to collecting and reporting data [13,14] with no results available to our knowledge. In the past year, the American Heart Association journals began publicly posting such information for authors, reviewers, and editorial board members across their journal portfolio, but the results are on a website not published in a journal, so are more difficult to find. They reported that from July 2020 to June 2021, the proportion of women was 26% of invited authors and 21% of invited reviewers. These proportions were 27% and 22% from July 2021 to June 2022. The editorial boards were 29% women in 2020-2021 and 30% women in 2021-2022 [15]. Although these percentages are lower than the percentage of female members of this organization 34% [16], trends are going in the right direction. 8 | CONCLUSIONS How should we grade RPTH’s efforts to achieve our equity, diversity, and inclusion goals? We suggest a grade of B+. That we report statistics at all boosts our grade substantially. Author and editorial team gender generally mirrors the distribution of the ISTH membership. We have been able to collect self-reported race or ethnicity, with increasing willingness of people to respond. We are increasing the representation of authors in less research-intensive and lessresourced areas of the world, although the proportions remain small; we hope that the evolving editorial team composition may lead to future improvement. We are failing in the representation of female peer reviewers. At least 1 additional report will be published before Dr. Cushman’s term as Editor in Chief ends in December 2023. It is hoped that this work will be adopted by other journals. $XWKRUV E͘ ŵĞƌŝĐĂ ƵƌŽƉĞ ƐŝĂ KĐĞĂŶŝĂ ^͘ ŵĞƌŝĐĂ DŝĚĚůĞ ĂƐƚ ĨƌŝĐĂ 5HYLHZHUV (GLWRULDO 7HDP FIGURE 4 Distribution of region of the world for authors, reviewers, and editorial team. 4 of 5 - EDITORIAL
KEYWORDS authorship, women, peer review, publication, diversity, equity ACKNOWLEDGMENTS The authors acknowledge managing editor Zachary Gillan and the RPTH associate editors Pantep Angchaisuksiri, Cihan Ay, Suzanne Cannegieter, Lana Castellucci, Johnny Mahlangu, Vania Morelli, Suely Rezende, Yotis Senis, Kristen Sanfilippo, Bethany Samuelson Bannow, Michelle Sholzberg, Henri Spronk, and Neil Zakai. Elizabeth C. Pendlebury BA1 Mary Cushman MD, MSc2 1University of Vermont, Burlington, Vermont, USA 2Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA Correspondence Mary Cushman, Larner College of Medicine at the University of Vermont, 360 South Park Dr, Colchester, VT 05446, USA. Email: mary.cushman@uvm.edu TWITTER Mary Cushman @MaryCushmanMD REFERENCES [1] Cushman M. Diversity and inclusion in a new medical journal: advancing science in the 21st century. Res Pract Thromb Haemost. 2018;2:620–1. [2] Cushman M. #WomenInMedicine: progress in gender equity at Research and Practice in Thrombosis and Haemostasis. Res Pract Thromb Haemost. 2019;3:560–2. [3] Pendlebury EC, Cushman M. Diversity, equity, and inclusion in publishing: calling thrombosis and hemostasis journals to action in support of women. Res Pract Thromb Haemost. 2020;4:1076–9. [4] Pendlebury EC, Cushman M. Annual report on equity, diversity, and inclusion: research and Practice in Thrombosis and Haemostasis is meeting its goals. Res Pract Thromb Haemost. 2021;5: e12610. [5] Gordon SE. Progress on the representation of women in JGP. J Gen Physiol. 2019;151:1157–8. [6] International Society on Thrombosis and Haemostasis. ISTH mission and core values, https://www.isth.org/page/Mission [accessed December 28, 2022]. [7] Batumalai V, Kumar S, Sundaresan P. Trends in gender of first and senior authors of articles published in JMIRO. J Med Imaging Radiat Oncol 2022. [8] Selvakumar S, Zagales I, Newsome K, Spardy J, Santos R, Boneva D, et al. Gender distribution & rank of authorship in surgical literature. Am Surg. 2022:31348221121536. [9] Kalidasan D, Goshtasebi A, Chrisler J, Brown HL, Prior JC. Prospective analyses of sex/gender-related publication decisions in general medical journals: editorial rejection of populationbased women’s reproductive physiology. BMJ Open. 2022;12: e057854. [10] Aquino-Canchari CR, Chavez-Bustamante SG, Benites-Ibarra CA, Quijano-Escate R, Arroyo-Hernandez H. Female participation in the editorial committees of medical journals in Latin America. Biomedica. 2022;42:355–63. [11] Cushman M. Are women equal? Considering impact of therapeutic abortion bans on science. Res Pract Thromb Haemost. 2022;6: e12742. [12] Baobeid A, Faghani-Hamadani T, Sauer S, Boum Y 2nd, HedtGauthier BL, Neufeld N, et al. Gender equity in health research publishing in Africa. BMJ Glob Health. 2022;7. [13] Doubeni CA, Corley DA, Peek RM Jr. Advancing diversity, equity, and inclusion in scientific publishing. Gastroenterology. 2022;162:59– 62. [14] The Editors Of The Lancet Group. The Lancet Group’s commitments to gender equity and diversity. Lancet. 2019;394:452–3. [15] American Heart Association. AHA journals demographic information, https://www.ahajournals.org/journal-demographics [accessed December 28, 2022]. [16] Cushman M. Women authorship in cardiovascular science: a call to track and report to achieve equity. J Am Heart Assoc. 2022;11: e025456. EDITORIAL - 5 of 5
Res Pract Thromb Haemost. 2022;6:e12712. Պ|Պ1 of 12 https://doi.org/10.1002/rth2.12712 wileyonlinelibrary.com/journal/rth2 !;1;b;7Ĺ ƐѶ -m-u ƑƏƑƑՊ|Պ!;bv;7Ĺ ƑѶ -u1_ ƑƏƑƑՊ|Պ 11;r|;7Ĺ Ɣ rubѴ ƑƏƑƑ DOI: 10.1002/rth2.12712 ORIGINAL ARTICLE Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial Marc Blondon MD1 Պ| Sara Cereghetti MD2Պ| Jérôme Pugin MD2Պ| Christophe Marti MD3Պ| Pauline Darbellay Farhoumand MD3Պ| Jean-Luc Reny PhD3 Պ| Alexandra Calmy MD4Պ| Christophe Combescure PhD5Պ| Lucia Mazzolai MD6Պ| Olivier Pantet MD7Պ| Zied Ltaief MD7Պ| Marie Méan MD8Պ| Sara Manzocchi Besson MD9Պ| Séverin Jeanneret MD10Պ| Hans Stricker MD11Պ| Helia Robert-Ebadi MD1 Պ| Pierre Fontana PhD1 Պ| Marc Righini MD1 Պ| Alessandro Casini MD1 This is an open access article under the terms of the u;-|b; ollomv ||ub0|bomŊ om oll;u1b-ѴŊ o ;ubv License, which permits use and distribution in -m l;7blķ ruob7;7 |_; oub]bm-Ѵ ouh bv ruor;uѴ 1b|;7ķ |_; v; bv momŊ1 oll;u1b-Ѵ -m7 mo lo7b=b1-|bomv ou -7-r|-|bomv -u; l-7;ĺ š ƑƏƑƑ $_; |_ouvĺ Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). 1 bbvbom o= m]boѴo] -m7 ;lov|-vbvķ Geneva University Hospitals and Faculty o= ;7b1bm;ķ ;m;-ķ "b|;uѴ-m7 2Division of Intensive Care, Geneva University Hospitals and Faculty of ;7b1bm;ķ ;m;-ķ "b|;uѴ-m7 3 bbvbom o= ;m;u-Ѵ m|;um-Ѵ ;7b1bm;ķ Geneva University Hospitals and Faculty o= ;7b1bm;ķ ;m;-ķ "b|;uѴ-m7 4 (ņ " &mb|ķ bbvbom o= m=;1|bov Disease, Geneva University Hospitals and -1Ѵ| o= ;7b1bm;ķ ;m;-ķ "b|;uѴ-m7 ƔClinical Research Center, Geneva University Hospitals and Faculty of ;7b1bm;ķ ;m;-ķ "b|;uѴ-m7 6 bbvbom o= m]boѴo]ķ ;m|u; ovrb|-Ѵb;u Universitaire Vaudois, Lausanne, "b|;uѴ-m7 7Division of Intensive Care, Centre Hospitalier Universitaire Vaudois, -v-mm;ķ "b|;uѴ-m7 8 bbvbom o= m|;um-Ѵ ;7b1bm;ķ ;m|u; Hospitalier Universitaire Vaudois, -v-mm;ķ "b|;uѴ-m7 9&mb| o= m]boѴo]ķ ॖ rb|-Ѵ 7 (-Ѵ-bvķ "bomķ "b|;uѴ-m7 10 bbvbom o= m|;mvb; -u;ķ ॖ rb|-Ѵ 7 (-Ѵ-bvķ "bomķ "b|;uѴ-m7 11 bbvbom o= m]boѴo]ķ o1-umo !;]bom-Ѵ ovrb|-Ѵķ o1-umoķ "b|;uѴ-m7 Abstract Background: ovrb|-Ѵb;7 r-|b;m|v b|_ ( Ŋ ƐƖ v==;u;7 bmb|b-ѴѴ =uol _b]_ u-|;v of venous thromboembolism (VTE), with possible associations between therapeutic anticoagulation and better clinical outcomes in observational studies. Objective: To test whether therapeutic anticoagulation improves clinical outcomes in v;;u; ( Ŋ ƐƖĺ Patients/Methods: m |_bv lѴ|b1;m|;uķ or;mŊѴ -0;Ѵķ u-m7olb;7 1om|uoѴѴ;7 |ub-Ѵķ ; u;Ŋ 1ub|;7 -1|;Ѵ bѴѴ l;7b1-Ѵ ( Ŋ ƐƖ r-|b;m|v b|_ Ŋ7 bl;u >1000 ng/ml or critically bѴѴ ( ŊƐ Ɩ r-|b;m|v bm =ou "bvv _ovrb|-Ѵvķ =uol rubѴ ƑƏƑƏ m|bѴ m; ƑƏƑƐķ b|_ - ƒƏŊ7 - =oѴѴoŊ rĺ -u|b1br-m|v ;u; u-m7olb;7 |o bmŊ _ovrb|-Ѵ |_;u-r;|b1 -m|b1o-]Ŋ Ѵ-|bom ;uvv ѴoŊ7 ov; -m|b1o-]Ѵ-|bom bm -1|;Ѵ bѴѴ r-u|b1br-m|vņbm|;ul;7b-|;Ŋ 7ov; anticoagulation in critically ill participants, with enoxaparin or unfractionated hepŊ -ubmvĺ $_; rubl-u o|1ol; -v - 1;m|u-ѴѴ -7f7b1-|;7 1olrovb|; o= ƒƏŊ7 - -ѴѴŊ 1-v; mortality, VTE, arterial thrombosis, and disseminated intravascular coagulopathy (DIC), with screening for proximal deep vein thrombosis. Results: lom] ƐƔƖ r-u|b1br-m|vķ ƔƔĺƒѷ ;u; 1ub|b1-ѴѴ bѴѴ -m7 ƖƓĺƒѷ u;1;b;7 1ou|bŊ 1ov|;uob7vĺ ;=ou; v|7 bm1Ѵvbomķ rѴlom-u ;l0oѴbvl _-7 0;;m ;1Ѵ7;7 bm ƕƐĺƕѷĺ $_; rubl-u o|1ol; o11uu;7 bm ƓņƕƖ r-u|b1br-m|v u-m7olb;7 |o |_;u-r;|b1 -m|bŊ 1o-]Ѵ-|bom -m7 ƓņѶƏ |o Ѵoņbm|;ul;7b-|; -m|b1o-]Ѵ-|bom ŐƔĺƓѷ vĺ ƔĺƏѷĸ ubvh 7b==;uŊ ence +ƏĺƓѷĸ -7fv|;7 _--u7 u-|bo Əĺƕѵķ ƖƔѷ 1om=b7;m1; bm|;u-Ѵ ƏĺƐѶŋ ƒĺƑƐőķ bm1Ѵ7bm] |_u;; 7;-|_v bm ;-1_ ]uorĺ ѴѴ rubl-u o|1ol;v -m7 l-fou 0Ѵ;;7bm] Őn = 3) occurred Reprinted from Res Pract Thromb Haemost. 2022;6:e12712 htt ps://doi.org/10.1002/rth2.12712
RkJQdWJsaXNoZXIy MTk3NTQxMg==